Avant Technologies and Ainnova Tech have announced that they are exploring the integration of early dementia detection into Ainnova’s AI-driven platform, Vision AI.
The partnership aims to expand AI-powered early detection and preventative health solutions globally.
Avant Technologies and Ainnova Tech are investigating options to incorporate a patented technology for early dementia detection into their Vision AI platform.
The platform employs AI algorithms and hardware to analyse a five-minute blood test, enhancing the two companies’ technology portfolio and strengthening their partnership.
The Vision AI platform currently utilises an automated, low-cost retinal imaging device to conduct comprehensive preventive risk screenings.
It assesses risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using two retinal images, blood pressure, and laboratory test information.
Ainnova Tech, a Nevada-based healthtech startup with headquarters in Costa Rica and Texas, is recognised for its advanced approach to early disease detection.
The company has earned multiple global awards and established partnerships with hospitals and medical device companies.
Avant Technologies, an emerging healthcare technology company, aims to drive progress and efficiency across various industries by leveraging AI and machine learning.
Ainnova CEO and Ai-nova Acquisition Corp. (joint venture company) Board of Directors’ member Vinicio Vargas said: “This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.
“Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection.”
